Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 2 trial, adults with previously untreated colorectal cancer and liver metastases will receive retlirafusp alfa in combination with bevacizumab and CAPOX chemotherapy, with the option of short-course radiotherapy. The study will monitor safety and how well the treatment can shrink tumors or slow disease progression, using RECIST v1.1 criteria for measurement. Participants must have good performance status and adequate organ function, and must be eligible for surgery if conversion of disease to resectability is possible. The goal is to explore whether this combination can convert unresectable liver metastases to operable disease while maintaining manageable toxicity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provide signed written informed consent and voluntarily agree to participate in this study.
2. Age ≥ 18 years and ≤ 75 years.
3. Histologically confirmed colorectal adenocarcinoma.
4. Liver metastasis confirmed by imaging or pathology.
5. Have not received any prior anti-cancer therapy.
6. At least one measurable lesion according to RECIST v1.1.
7. pMMR/MSS status confirmed by a local testing center, or unknown status.
8. Be able to swallow tablets.
9. ECOG PS 0-1
10. Have no contraindications for surgery.
11. Have adequate major organ function.

Exclusion Criteria:

1. Have a history of allergy to monoclonal antibodies, any component of retlirafusp alfa, bevacizumab, capecitabine, oxaliplatin, or other platinum-based agents.
2. Have previously received or are currently receiving any of the following treatments:

   1. Any anti-tumor therapy including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
   2. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 2 weeks prior to the first dose of study drug (at a dose \> 10 mg/day prednisone or equivalent). Inhaled or topical corticosteroids, and adrenal replacement therapy at doses \> 10 mg/day prednisone or equivalent, are permitted in the absence of active autoimmune disease.
   3. Receipt of live attenuated vaccine within 4 weeks prior to the first dose of study drug.
   4. Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.
3. Have any active autoimmune disease or history of autoimmune disease, including but not limited to interstitial pneumonitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (patients on hormone replacement therapy may be considered for inclusion). Patients with psoriasis or childhood asthma/allergy that has completely resolved and requires no intervention in adulthood may be considered for inclusion, but those requiring medical intervention with bronchodilators are not eligible.
4. Have a history of immunodeficiency, including HIV-positive test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.
5. Have poorly controlled cardiac symptoms or diseases, including but not limited to: (1) heart failure of New York Heart Association (NYHA) class ≥ II; (2) unstable angina; (3) myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmias that have not been clinically intervened or remain poorly controlled after intervention.
6. Have experienced a severe infection (CTCAE grade \> 2) within 4 weeks prior to the first dose of study drug, such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications; or have evidence of active pulmonary inflammation on baseline chest imaging, or have signs/symptoms of infection or require oral or intravenous antibiotic therapy within 14 days prior to the first dose of study drug (except for prophylactic antibiotic use).
7. Have active pulmonary tuberculosis infection by history or CT examination, or a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or a history of active pulmonary tuberculosis infection \> 1 year ago without adequate treatment.
8. Have hepatitis B (HBV DNA ≥ 2000 IU/mL or ≥ 10⁴ copies/mL), or hepatitis C (positive anti-HCV antibody and HCV RNA above the lower limit of detection of the assay).
9. Have been diagnosed with another malignancy within 5 years prior to the first dose of study drug, except for malignancies with a low risk of metastasis or death (5-year survival rate \> 90%), such as adequately treated basal cell carcinoma or squamous cell skin cancer, or cervical carcinoma in situ, which may be considered for inclusion.
10. Are pregnant or breastfeeding.

Where it's running

• Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Tao Zhang, MD — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• Study coordinator: Zhenyu Lin, MD
• Email: whxhlzy@hust.edu.cn
• Phone: 027-83262683

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with standard chemotherapy and bevacizumab, with or without INCA33890, for metastatic microsatellite-stable colorectal cancer

  This trial will test whether adding a new drug, INCA33890, to standard chemotherapy and bevacizumab helps people with metastatic microsatellite-stable colorectal cancer respond better or live longer.

  Recruiting at 168 sites Phase 3 Incyte Corporation · Mobile, Alabama and 296 other locations · NCT07284849

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.